What did @drjolenebrighten actually say?
In this clip, Dr. Gersh argues that the estrogens most commonly prescribed to women, including conjugated equine estrogens from horse urine and ethinyl estradiol in birth control pills, are not "real human estrogens." Her conclusion is pointed: these synthetic forms create hormonal imbalance, drive inflammation, and can "stimulate" estrogen receptor-positive cancers, even if they don't directly cause them.
She draws a careful line between causation and stimulation, which is worth noting. The exact framing is that synthetic estrogens contribute to "uncontrolled proliferation" that can "underlie stimulation, not causation, but stimulation of cancers that have estrogen receptor positivity." That distinction is doing a lot of work in an argument that could easily be read as a blanket cancer warning against hormone therapy.
Does the science back this up?
Partially, yes. The distinction between estrogen types is scientifically real and clinically meaningful. But the cancer framing is more complicated than the clip lets on, and some of the evidence cuts in the opposite direction.
Ethinyl estradiol is genuinely different from endogenous 17-beta estradiol. It resists hepatic metabolism, increases hepatic protein synthesis more than bioidentical estrogen does, and produces a different receptor-binding profile (Stanczyk et al., 2013, Steroids). Conjugated equine estrogens contain over 10 different estrogen compounds, including equilin and equilenin, which are not found in the human body. So the "not a real human estrogen" argument has a biochemical basis.
The cancer link is where things get messier. The Women's Health Initiative, which used conjugated equine estrogens plus medroxyprogesterone acetate, did show an increased breast cancer risk in combined HRT users (Rossouw et al., 2002, JAMA). But estrogen-only arms, used in women without a uterus, showed a reduced breast cancer risk. That nuance is missing from this clip entirely.
What did they get wrong (or right)?
They got the pharmacology directionally right. Ethinyl estradiol is not bioidentical, and conjugated equine estrogens contain non-human compounds. That is accurate. The inflammation and receptor-binding arguments are supported by mechanistic literature (Stanczyk et al., 2013).
What is misleading is the implied equivalency between oral synthetic estrogens and all estrogen therapy. Transdermal 17-beta estradiol, which is bioidentical and avoids first-pass hepatic metabolism, has a substantially different safety profile. Research by Canonico et al. (2007, Circulation) found no increased venous thromboembolism risk with transdermal estradiol, unlike oral estrogens. The clip does not make this distinction, which matters enormously for how patients interpret hormone therapy risk.
The cancer framing also glosses over the difference between unopposed estrogen and combined therapy, which is one of the most important variables in breast cancer risk. Attributing cancer stimulation broadly to synthetic estrogens, without specifying progestin co-administration, is a meaningful omission.
What should you actually know?
The type of estrogen, the route of delivery, and whether a progestin is added are not minor details. They are the variables that determine risk. Oral synthetic estrogens behave differently from transdermal bioidentical estradiol. This is not fringe science. It is reflected in current clinical guidance from the Menopause Society (formerly NAMS) and in European prescribing norms, where transdermal estradiol has been first-line for years.
Estrogen receptor-positive cancers are a real concern, and estrogen does promote proliferation in ER-positive tissue. That is established biology. But the relationship between exogenous estrogen and cancer risk is not a simple dose-response story. Timing, patient history, formulation, and progestin type all modify risk. The "stimulation not causation" framing is a reasonable distinction, but it can still generate unwarranted fear about hormone therapy broadly when delivered without the full context.
If you are weighing hormone therapy options, route of administration and estrogen type are legitimate questions to ask your prescriber. They have clinically meaningful answers.